insights_auto
Why is GSK down 2,57%?
Dive Deeperchevron_right
GSK:LON
GSK plc
GBX 1.744,50
arrow_downward
-2,57%(-46,00) 1D
8 ຕ.ລ., 15 ໂມງ 51 ນາທີ 10 ວິນາທີ GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
GBX 1.773,00
High
GBX 1.773,00
Low
GBX 1.741,00
Mkt. cap
71,25 ຕື້
Avg. vol.
5,51 ລ້ານ
Volume
2,49 ລ້ານ
Dividend
3,90%
Quarterly dividend
GBX 17,00
Ex-dividend date
13 ສ.ຫ. 2026
P/E ratio
14,78
52-wk high
GBX 2.282,00
52-wk low
GBX 1.592,00
EPS
GBX 1,18
Shares outstanding
4,32 ຕື້
No. of employees
67 ພັນ
Open
GBX 1.773,00
High
GBX 1.773,00
Low
GBX 1.741,00
Mkt. cap
71,25 ຕື້
Avg. vol.
5,51 ລ້ານ
Volume
2,49 ລ້ານ
Dividend
3,90%
Quarterly dividend
GBX 17,00
Ex-dividend date
13 ສ.ຫ. 2026
P/E ratio
14,78
52-wk high
GBX 2.282,00
52-wk low
GBX 1.592,00
EPS
GBX 1,18
Shares outstanding
4,32 ຕື້
No. of employees
67 ພັນ
News stories
From web sources and news partners
TipRanks
·
23 ນາທີກ່ອນ
GSK Director Wendy Becker Joins Tesco Board as Non-Executive
Financial-News.co.uk
·
2 ຊົ່ວໂມງກ່ອນ
GSK Passive Income Stock Draws ISA Buyers Despite Cost-Savings Push
Stock Titan
·
3 ຊົ່ວໂມງກ່ອນ
Viola Davis says shingles pain was 9 out of 10. She couldn't work.
AD HOC NEWS
·
4 ຊົ່ວໂມງກ່ອນ
GSK reported Cabenuva trial success. GSK stock trades 1.38 percent below its prior close.
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 ພັນ
Founded27 ທ.ວ. 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com